Patel Mrinali, Paulus Yannis M, Gobin Y Pierre, Djaballah Hakim, Marr Brian, Dunkel Ira J, Brodie Scott, Antczak Christophe, Folberg Robert, Abramson David H
Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, USA.
Ophthalmic Genet. 2011 Sep;32(3):147-50. doi: 10.3109/13816810.2010.544530. Epub 2011 Mar 29.
Preclinical studies demonstrate that cardiac glycosides such as ouabain and digoxin have antitumor effects on retinoblastoma cells in vitro and in a xenograft murine model of retinoblastoma.
Based on these findings, we report a case of intra-arterial followed by systemic oral digoxin therapy in a patient with unilateral retinoblastoma that had failed prior intra-arterial chemotherapy.
Oral administration of digoxin produced no effect, while intra-arterial digoxin therapy produced a modest but measurable response that was likely limited by the inability to achieve sustained drug concentration in the eye.
This case highlights both the potential promise and limitations of cardiac glycoside therapy in retinoblastoma.
临床前研究表明,哇巴因和地高辛等强心苷在体外以及视网膜母细胞瘤的异种移植小鼠模型中对视网膜母细胞瘤细胞具有抗肿瘤作用。
基于这些发现,我们报告了1例单侧视网膜母细胞瘤患者,该患者先前的动脉内化疗失败,先接受了动脉内然后全身性口服地高辛治疗。
口服地高辛未产生效果,而动脉内地高辛治疗产生了适度但可测量的反应,这可能受到无法在眼中实现持续药物浓度的限制。
该病例凸显了强心苷疗法在视网膜母细胞瘤治疗中的潜在前景和局限性。